Kuros Biosciences AG / Key word(s): Study resultsKuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial 13.07.2023 / 19:29 CET/CEST First investigational trial of drug-biologic bone graft for spinal fusion 50 patients have been enrolled in the Phase 2 trial Potential to address $2.2B ma...

Related Keywords

United States , Switzerland , Zurich , Züsz , Netherlands , Swiss , Daniel Geiger , Mary Ann Chang , Kuros Biosciences , John Chi , R Todd Allen , Swiss Exchange , Drug Administration , Biosciences Announces Completion , Chief Executive Officer , Investigational New Drug , Sci Advisors , Transforaminal Lumbar Interbody Fusion ,